Contineum Therapeutics, Inc. Class A Common Stock
HealthcareNASDAQ:CTNM · NASDAQ Global Select
+$0.02 today
Vol 0.11M · Avg 0.26M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$60.0M -41.9% | -$42.3M -286.0% | $22.7M +193.7% | -$24.3M +16.4% | -$29.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $323.0K +25.2% | $258.0K +32.3% | $195.0K -40.7% | $329.0K +1.2% | $325.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $10.0M +47.5% | $6.8M +206.6% | $2.2M +15.2% | $1.9M +10.2% | $1.7M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$6.0M -213.2% | $5.3M +620.9% | -$1.0M +19.2% | -$1.3M -1273.1% | $108.0K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$869.0K -176.2% | $1.1M | $0 +100.0% | -$230.0K -109.1% | -$110.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$5.2M -223.3% | $4.2M +509.5% | -$1.0M +1.3% | -$1.0M -575.7% | $218.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $344.0K +111.5% | -$3.0M +37.3% | -$4.8M -251.5% | $3.1M +468.4% | $553.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$55.3M -68.4% | -$32.8M -269.8% | $19.3M +196.2% | -$20.1M +23.4% | -$26.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$231.0K +55.1% | -$514.0K -24.2% | -$414.0K -250.8% | -$118.0K +29.8% | -$168.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 -100.0% | $20.0K | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$162.5M +28.2% | -$226.4M -59.6% | -$141.9M -119.3% | -$64.7M +3.1% | -$66.8M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $159.0M +1.2% | $157.2M +104.9% | $76.7M -11.9% | $87.1M +4308.7% | $2.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$3.7M +94.7% | -$69.7M -6.4% | -$65.6M -394.0% | $22.3M +134.3% | -$65.0M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 +100.0% | -$3.8M -200.0% | -$1.3M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $112.7M +4.1% | $108.2M | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 +100.0% | -$28.0K -600.0% | -$4.0K | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $790.0K +529.3% | -$184.0K -1326.7% | $15.0K -86.7% | $113.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $112.7M +3.4% | $109.0M +94.0% | $56.2M +4634.0% | -$1.2M -101.6% | $79.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $53.7M +736.2% | $6.4M -35.6% | $10.0M +960.4% | $939.0K +108.2% | -$11.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$55.5M -66.5% | -$33.4M -276.2% | $18.9M +193.6% | -$20.2M +23.4% | -$26.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Candel Therapeutics, Inc.
NASDAQ:CADL
$469.95M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Mereo BioPharma Group plc
MREO
$48.68M
SEC Filings
Recent regulatory filings
No filings found.
Does CTNM generate free cash flow?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) generated -$55,543,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does CTNM produce?
Operating cash flow was -$55,312,000.00, before capital expenditures of $231,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.